Lyell Immunopharma, Inc.
LYEL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001806952
In the last 90 days, Lyell Immunopharma, Inc. insiders filed 0 open-market purchases and 10 sales; 87 institutions reported holding it in 13F filings for Q2 2026, worth $178.0M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Lyell Immunopharma, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- 0 vs. Q1 2023
- Shares held
- 122.2M
- +4.46M (+3.8%) vs. Q1 2023
- Total value
- $388.7M
- +$110.8M (+39.9%) vs. Q1 2023
- New holders
- 16
- 31 more added
- Sold out
- 16
- 34 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LYEL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 87 | $178.0M |
| Q1 2026 | 74 | $251.1M |
| Q4 2025 | 69 | $371.9M |
| Q3 2025 | 59 | $164.9M |
| Q2 2025 | 69 | $81.9M |
| Q1 2025 | 112 | $81.8M |
| Q4 2024 | 105 | $95.9M |
| Q3 2024 | 117 | $176.6M |
| Q2 2024 | 120 | $194.2M |
| Q1 2024 | 127 | $296.8M |
| Q4 2023 | 119 | $255.2M |
| Q3 2023 | 106 | $180.1M |
| Q2 2023 | 99 | $388.7M |
| Q1 2023 | 99 | $277.9M |
| Q4 2022 | 95 | $404.8M |
| Q3 2022 | 93 | $823.5M |
| Q2 2022 | 75 | $688.6M |
| Q1 2022 | 79 | $502.7M |
| Q4 2021 | 77 | $662.2M |
| Q3 2021 | 62 | $1.22B |
| Q2 2021 | 52 | $1.29B |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Lyell Immunopharma, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −226,948−100.0% | Sold out |
| Vident Investment Advisory, LLC | 0 | $0 | 0.00% | −221,112−100.0% | Sold out |
| Eagle Health Investments LP | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Cornercap Investment Counsel Inc | 0 | $0 | 0.00% | −90,172−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −73,600−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −67,953−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −49,458−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −16,353−100.0% | Sold out |
| Zacks Investment Management | 0 | $0 | 0.00% | −10,831−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −2,300−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −1,276−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −939−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −831−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −18−100.0% | Sold out |